1. Medtech Insight

FDA clears Integra's LICOX system:

Integra Neurosciences, a division of Plainsboro, New Jersey-based Integra LifeSciences Holdings, has received US FDA 510 (k) clearance to market its LICOX brain tissue oxygen monitoring system. The device, which is manufactured by German-based GMSmbH, provides continuous quantitative regional monitoring of dissolved oxygen and temperature in body fluids and tissues. The small size and long-term stability of the system's sensors make the product useful for critical care and intraoperative monitoring, says the company, which plans to launch the product in the first quarter of the year.

Integra Neurosciences, a division of Plainsboro, New Jersey-based Integra LifeSciences Holdings, has received US FDA 510 (k) clearance to market its LICOX brain tissue oxygen monitoring system. The device, which is manufactured by German-based GMSmbH, provides continuous quantitative regional monitoring of dissolved oxygen and temperature in body fluids and tissues. The small size and long-term stability of the system's sensors make the product useful for critical care and intraoperative monitoring, says the company, which plans to launch the product in the first quarter of the year.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Medtech Insight

Execs On The Move: August 4–8, 2025

 
• By Medtech Insight Team

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

NAD Alerts Agendia Over Endorsing Physician’s Ties To Firm

 
• By Elizabeth Orr

The National Advertising Division (NAD) alerted Agendia to improve disclosure regarding a physician endorsing its MammaPrint test. The physician's ties to Agendia were inadequately revealed in LinkedIn posts.

FDA Ends Effort To Regulate LDTs By Rescinding Final Rule

 
• By Brian Bossetta

Just a year and four months after publishing a final rule that would have allowed it to regulate laboratory developed tests as medical devices, the US FDA has rescinded the controversial measure, finally putting an end to the saga.